By Ellen Capon (Drug Target Review)2023-10-17T16:00:14
Research into how the amino acid arginine drives metabolic reprogramming offers promise for liver cancer treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-26T13:58:00Z
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2023-09-27T13:56:39
Sponsored by Euretos
2023-03-20T13:41:33
Sponsored by Bio-Techne
2023-07-04T10:05:58
Sponsored by Revvity
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2023-01-06T10:25:33
Sponsored by Leica Microsystems
Site powered by Webvision Cloud